New tuberculosis drug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance. To minimise turnaround time, rapid DST will need to be prioritised, but developers of these assays will need better data about the molecular mechanisms of resistance. Eff orts are underway to link mutations with drug resistance and to develop strain collections to enable assessment of new diagnostic assays. In resource-limited settings, DST might not be appropriate for all patients with tuberculosis. Surveillance data and modelling will help country stakeholders to design appropriate DST algorithms and to decide whether to change drug regimens. Finally, development of practical DST assays is needed so that, in countries where surveillance and modelling show that DST is advisable, these assays can be used to guide clinical decisions for individual patients. If combined judiciously during both development and implementation, new tuberculosis regimens and new DST assays have enormous potential to improve patient outcomes and reduce the burden of disease.
Introduction
Patient care algorithms can be improved in two main ways: by rethinking and reorganising existing methods and technologies, and by introducing new technologies. In recent decades, national tuberculosis programmes have used existing technologies more eff ectively than in previous decades, achieving substantial results. 1 But further improvement is restricted by outdated and inadequate methods used to fi ght the epidemic: a vaccine with limited eff ectiveness; a drug regimen that is long and that places substantial demands on patients and health-care systems; and a diagnostic technique (smear microscopy) that detects only half of all cases and does not assess drug resistance of the infecting Mycobacterium tuberculosis strain. 2 As eff orts to improve these methods accelerate, investigators now have to consider how these various approaches will work together within a health system. Rapid development of resistance could occur if new drugs are added to failing regimens, or if combination regimens are used widely in populations that have substantial existing resistance to some of the drugs in those combinations. In some cases this resistance might leave only one eff ective drug in a regimen, increasing the chance of developing additional resistance and severely limiting the antimicrobial arsenal even further. Therefore, new tuberculosis regimens 3 cannot be introduced without development of drug susceptibility testing (DST) assays suited to the new regimens. DST can be used to monitor patterns of emerging drug resistance and to direct patients towards appropriate therapy, but careful analysis is needed to establish the optimum DST strategy for each new drug regimen and each diff erent epidemiological context.
The primary backbone of tuberculosis treatment has not changed for decades; thus, susceptibility tests for
• Advances in new drug regimens and diagnostics for tuberculosis, including drug susceptibility testing (DST), are exciting; however, strategies should be aligned to promote co-introduction for optimum results • Tuberculosis treatment should ideally be based on full information about drug susceptibility of the infecting strain; however, at least in the short term and in resource-limited settings, less comprehensive DST might be more feasible or advisable in some countries; potential gains from DST should be balanced against costs, complexity, and predicted loss to follow-up • DST and drug resistance surveillance are particularly important for existing and repurposed drugs, such as pyrazinamide and fl uoroquinolones, that are being tested in fi rst-line regimens and for which resistance already exists • DST should be rapid to maximise patient retention and ensure prompt treatment with eff ective regimens, thus minimising the generation and spread of resistance; a rapid DST assay will probably need to detect molecular, rather than phenotypic, correlates of resistance • To improve molecular tests, further research is needed to establish the genetic basis for resistance to existing and new drugs and to link each mutation with clinical eff ect; surveillance is needed to establish the background level of resistance • This information can be used by modellers to assess the potential eff ectiveness of diff erent scenarios of drug and diagnostic introduction; by product developers to better defi ne product specifi cations; and by country programmes and providers to better assess whether, and how, to adopt new products Series additional drugs have not received much attention. 4 But regimens with new tuberculosis drugs will change priorities for DST and drug resistance surveillance. Resistance against drugs in new fi rst-line regimens will be particularly important to test for, especially since existing tuberculosis drugs are easily available in the private sector-in large volumes, and with little or no regulation-in many high tuberculosis burden countries. 5 Through the Tuberculosis Diagnostics Research Forum, several partners are working to ensure that the necessary DST assays are developed in time for coimplementation with new tuberculosis drug regimens. The aim is to develop a framework for designing DST for new regimens. Such DST should meet at least the same performance criteria as DST for existing fi rst-line therapy. The ultimate goal is to have suffi cient information-including prevalence of existing resistance-so that all patients with tuberculosis can be confi dent that their regimen will be safe and eff ective.
To reach these goals, translational science is needed to provide the basis for molecular diagnostics development. Furthermore, surveillance data and modelling are needed to design DST protocols and to guide decisions on regimen changes. And, in countries where the surveillance and modelling show that DST assays are necessary, development and use of these assays are needed to guide clinical decision making for individual patients. In this Series paper, we discuss alignment of new tuberculosis regimens and tuberculosis DST, and we outline the actions needed for the optimum, coordinated introduction of new technologies for tuberculosis control.
Tuberculosis regimens: past, present, and future
First-line tuberculosis treatment has gradually evolved from monotherapy with streptomycin, to multidrug regimens of up to 24 months or more, and fi nally to the so-called short-course regimen now used in most highburden countries. 6 This regimen is a 6 month course of treatment denoted as 2HRZE/4HR: a 2 month intensive phase of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) followed by a 4 month continuation phase of isoniazid and rifampicin. It has been the global standard fi rst-line tuberculosis treatment for decades.
The duration of the 6 month regimen puts substantial demands on health-care systems and patients. 7, 8 Meanwhile, second-line tuberculosis treatment, for patients with multidrug-resistant (MDR) tuberculosis (defi ned by resistance to both isoniazid and rifampicin), is based only on observational studies and expert opinion. 9 These multidrug regimens of 18-24 months are toxic, expensive, and of limited eff ectiveness. 10 The inadequacy of these regimens, which has become increasingly evident as more people are diagnosed with MDR tuberculosis, has led to eff orts to fi nd and develop new tuberculosis drug regimens that would shorten fi rst-line treatment, avoid drug-drug interactions with antiretroviral therapy, and improve second-line treatment. 3, 11 Two phase 3 trials of shorter duration fi rst-line tuberculosis treatment have now completed patient enrolment and treatment. The OFLOTUB trial 12 replaced ethambutol with the fl uoroquinolone gatifl oxacin in a 4 month regimen, although gatifl oxacin has subsequently lost regulatory approval in many countries because of adverse events. The REMoxTB trial 13 replaced either isoniazid or ethambutol with the fl uoroquinolone moxifl oxacin (M) in two experimental, 4 month regimens (2HRZM/2HRM and 2MRZE/2MR). Results from REMoxTB are expected in late 2013; if positive, regulatory approval will be sought in 2014 and a national launch could start as early as 2015.
Next-generation, fi rst-line regimens are likely to include several new drugs.
14 Clinically, the most advanced regimen 15, 16 in this category is known as PaMZ, a combination of the novel nitroimidazo-oxazine PA-824, moxifl oxacin, and pyrazinamide. This regimen has the potential not only to shorten the duration of fi rst-line treatment, but also to treat a proportion of patients who would previously have needed second-line treatmentie, patients with MDR tuberculosis. 17 Finally, several tuberculosis drug candidates are in clinical development, but their optimised regimens have not yet been defi ned. Sutezolid (PNU-100480), an analogue of linezolid, is in phase 2a trials. More advanced are two new drugs that have been submitted for regulatory approval for treatment of MDR tuberculosis on the basis of phase 2b data. Bacterial burden was reduced more quickly when either bedaquiline (a diarylquinoline formerly known as TMC207) 18 or delamanid (a nitro-dihydro-imidazooxazole formerly known as OPC-67683) 19 was added, for 6 months, to an optimised background regimen for MDR tuberculosis. 18, 19 Bedaquiline was granted marketing approval by the US Food and Drug Administration on Dec 28, 2012. However, the extent to which these drugs can shorten and simplify MDR tuberculosis treatment will only be known after additional, multiyear phase 3 trials.
Tuberculosis diagnostics and DST: past and present practice
For decades, tuberculosis diagnosis in high-burden countries has relied almost entirely on smear microscopy, which is inexpensive but detects only half of all cases. 10 Additionally, smear microscopy does not provide any information about drug resistance, so most patients are put directly onto a standardised fi rst-line regimen without any knowledge of drug susceptibility. However, the increasing awareness of MDR tuberculosis 20 has drawn greater attention to the need for DST, with the initial focus on rifampicin DST for the diagnosis of MDR tuberculosis.
DST results are more likely to reach patients in a timely fashion when the DST technology allows for . These systems off er benefi ts such as reduced time to detection of resistance (from eff ectively 106 days with conventional DST to 20 days with line-probe assay and less than 1 day with the Xpert MTB/RIF assay), 21 thus allowing for more rapid initiation of MDR tuberculosis treatment. [22] [23] [24] Liquid culture and line-probe assays can be implemented in national and regional reference laboratories, and the Xpert MTB/RIF assay (an automated, cartridge-based, real-time PCR assay) in more peripheral sites such as subdistrict laboratories.
Before more recent developments, the primary method for tuberculosis DST involved the culturing of M tuberculosis; these phenotypic growth assays are slow and need sophisticated facilities with high biocontainment. For some MDR tuberculosis drugs, even phenotypic DST is not well established, and will need to be further researched because data are insuffi cient to calculate clinically relevant threshold concentrations. 25 Other phenotypic (growth-based) diagnostics, such as the microscopic observation drug-susceptibility assay and the nitrate reductase assay, might be an interim solution for resource-limited settings. 26 However, due to the very slow growth of M tuberculosis in phenotypic assays, truly rapid testing needs a molecular approach that avoids the need to grow M tuberculosis and instead uses molecular biology methods to detect resistanceassociated mutations in DNA. Such molecular assays are the primary focus of this Series paper.
Line-probe assays, though molecular, also present challenges. As with liquid culture, they need laboratory infrastructure that is not available at the periphery of the health-care system (eg, at health centres, district hospitals, or even most provincial hospitals), so they are not practical for routine testing of all individuals with confi rmed or suspected tuberculosis in most high-burden countries. 27 Such a step would need a massive sputum sample referral and transport system that typically does not exist. Instead, cultures and line-probe assays are used largely for patients at high risk of resistance-eg, those with persistent symptoms.
The Xpert MTB/RIF test, however, has great potential because it can be used at the district or subdistrict level. 28 It not only detects rifampicin resistance, but also detects far more tuberculosis cases than does smear microscopy, particularly in regions where many people are co-infected with HIV and tuberculosis. 21 As a result, the Xpert MTB/ RIF assay has been scaled up rapidly in South Africa, where it is used as the fi rst diagnostic for all individuals DST in centralised laboratories (status quo for most high-burden countries) DST in peripheral settings (eg, microscopy centres or district laboratories) 29 electricity, and maintenance requirements of this assay. 30 Although the price of the Xpert technology has been reduced to under US$10 per cartridge, this negotiated price is not available to the large number 5 of patients with tuberculosis in the private health sector in some high-burden countries. 31 The roll-out of the Xpert MTB/RIF assay has been associated with diffi culties that will probably also be applicable to DST development for new tuberculosis regimens. One major issue is positive predictive value. 32, 33 Even with a pooled sensitivity for rifampicin resistance of 94% and a pooled specifi city of 98%, 34 the latest iteration of the Xpert MTB/RIF assay has a positive predictive value for MDR tuberculosis of only about 50% or 67% when rifampicin resistance prevalence is 1% or 2%, respectively. 32 Such resistance values are typical in new patients with tuberculosis, and the low positive predictive value results in many false positives and a substantial demand for confi rmatory DST. 35 (Of note, however, even smear culture is not 100% accurate, so the true specifi city of the Xpert assay for rifampicin resistance might be higher than the initially reported 98%.) In many countries with low HIV or MDR tuberculosis prevalence, the issues of positive predictive value and costs have restricted the uptake of the Xpert MTB/RIF assay.
Future needs: alignment of new drug regimens and new diagnostics Selecting drugs to test and ways to test them
Which of the new drugs are the most important targets for future DST? Typically, DST has focused on drugs for which resistance has one or more of three consequences: it undermines treatment eff ectiveness, it increases the risk of resistance amplifi cation, or it strongly predicts resistance to other drugs (ie, acts as a triage assay). At present, rifampicin DST has been prioritised to diagnose MDR tuberculosis. 36 Evidence suggests isoniazid DST should also be done: substantial numbers of patients harbour isoniazid-resistant, rifampicinsusceptible strains, and patients with such strains have reduced treatment success. 37, 38 For implementation of the 4 month regimens, DST to detect susceptibility to rifampicin and fl uoroquinolones will be of interest, especially in countries that already do DST for rifampicin. For the PaMZ regimen, a rapid test for moxifl oxacin and pyrazinamide would probably be the fi rst priority, because clinically signifi cant resistance to PA-824 has not yet been shown. Development of DST for PA-824 and other new drugs will be prioritisedinitially for use in surveillance-as resistance to them develops and their use becomes more widespread.
After deciding which drugs to test, additional information is needed. To be rapid and clinically useful, a DST assay will probably need to be molecular. Therefore, information about resistance mutations-and the correlation of those mutations with clinical outcomes-is needed to form the basis for such a test.
The Xpert MTB/RIF assay's 94% sensitivity for detection of rifampicin resistance is only possible because almost every mutation contributing to rifampicin resistance is known and present in a short, defi ned DNA region. For fl uoroquinolones, however, incomplete knowledge of all contributing resistance mutations outside the quinolone-resistance determining regions of gyrA and gyrB means that sensitivity with such molecular methods would, on the basis of current knowledge, be limited to about 85%. 26, 39 As occurred recently for a line-probe assay for second-line drugs, when an assay has insuffi cient sensitivity, it might be recommended for use as a rule-in test only. 10, 35 Sensitivity might be enhanced by incorporation of additional, lowabundance mutations, but doing so might reduce specifi city to an unacceptable level-eg, if specifi city for each of fi ve independent mutations is 98%, the overall specifi city of a test including all fi ve mutations would be 0·98 5 or 90%. Other major issues, for fl uoroquinolones and other drugs, are the possibility of multigenic resistance and the diffi culty of detecting already-known mutations from a mixed population of bacilli. 40 DST for pyrazinamide poses even more challenges. The activation of pyrazinamide requires pH levels that are diffi cult to maintain in culture media, so phenotypic DST for pyrazinamide is inconsistent. Analysis of the sequence of one resistance gene (pncA) has been proposed as an alternative, although this approach might detect only about 90% of pyrazinamide resistance. 41 The mutations are spread along the entire length of the pncA gene, however, necessitating analysis of a fragment of roughly 700 bp. This drawback has led to the idea of testing for the presence of a wild-type gene (rather than testing for the presence of a specifi c mutation) as a way of ruling out resistance. In this approach, silent mutations, which do not confer resistance, would probably prevent hybridisation and thus yield false positives. These silent mutations, although rare, 42 need to be better characterised by standardised and validated culture-based pyrazinamide resistance assays and incorporated into a molecular testing algorithm.
To minimise these limitations, one priority in translational science is to link gene mutations to phenotypic resistance (ie, the amount of drug needed to inhibit bacterial growth). 43, 44 A second priority is to develop strain collections (preferably sequenced 45, 46 ) that will assist with the testing of new diagnostic assays and the development of genomic databases that would predict drug susceptibility phenotypes. For new drugs, isolates that develop resistance in vitro should be stored for later assessment, but their clinical signifi cance will be unclear until resistance is noted in clinical use. Compound availability for such clinical assessment and data for crucial breakpoints are likely to emerge only after regulatory approval of new tuberculosis drugs. Postmarketing studies will be important to identify treatment failures and resistance mechanisms.
Surveillance: a basis for decision making
Once translational science has provided a means to detect resistance, the next task will be to establish existing or emerging resistance levels via surveillance. Data for global drug resistance obtained through WHO's Global Project on Anti-TB Drug Resistance Surveillance is available from 135 of 194 member states, of which only 63 countries have continuous surveillance systems that use DST. 10 Generally, surveillance is restricted to activities that align with current rather than future treatment priorities. Most countries assess resistance to isoniazid, rifampicin, and ethambutol (pyrazinamide is often excluded, because of the methodological challenges already discussed) in new and retreated patients. Resistance to fl uoroquinolones is assessed only in patients with MDR tuberculosis because these patients are the only ones recommended to take fl uoroquinolones by WHO and the International Union Against Tuberculosis and Lung Diseases; however, a substantial amount of fl uoroquinolone use is believed to occur in fi rst-line tuberculosis treatment in the private sector of some countries. 5 Such data are insuffi cient to assess development and implementation priorities for new tuberculosis regimens and diagnostics. The key information gap for the REMoxTB regimens is fl uoroquinolone resistance in new patients. Although existing data suggest that such resistance is very low in most [47] [48] [49] but not all 50, 51 countries, the absence of such data for most high-burden countries makes it diffi cult for a country to assess the costeff ectiveness of the new regimen (ie, one factor in deciding whether to implement) or the most appropriate DST algorithm (ie, how to implement). And, for PaMZ, pyrazinamide resistance rates in both new and MDR tuberculosis patients are missing. For both moxifl oxacin and pyrazinamide resistance, some data are available from clinical trials, but nationally representative data are sorely needed. As new drugs with new mechanisms of action are adopted, surveillance will also be needed to monitor for the development of resistance to bedaquiline, delamanid, and others.
For surveillance data to be meaningful, the data should be representative of either a national or subnational population, be obtained using quality-assured assays, and distinguish between resistance rates in new patients and retreated patients. Ideally, DST surveys should be linked with treatment outcomes and patient care (although methods with high quality assurance would be needed) and would make use of new, high-throughput molecular methods that would be much faster than current growthbased assays. For example, with a suffi cient foundation of mutation data, 43 sequence-based assays can provide rapid and accurate information and, for many drugs, good correlation with DST obtained with liquid culture.
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DNA sequencing-as a centralised procedure-is more practical for surveillance than for patient care. But even for surveillance, it is important to develop fast and safe specimen preparation, transport methods that maintain stability of the DNA in the specimen, and templates, primers, barcodes, and standardised electronic reporting. Such systems should improve in accuracy as mutations with unknown association are obtained and analysed; however, while this knowledge is being accumulated, parallel implementation of phenotypic and molecular assays might be needed.
Collaboration with a country undertaking a drug resistance survey could provide an opportunity to pilot the technology and develop the systems described above. Such a study could provide the proof of principle and the data to validate such a system.
Modelling of alternative DST strategies
Drugs and diagnostics are implemented as individual elements of a larger, more complex tuberculosis management system. In the public health approach, all incoming patients are subdivided into just a few treatment pathways. Central to this management system are diagnostic algorithms, which consist of diff erent permutations of drugs to test for, the level of the health-care system at which the testing is done, the selection of the patient population eligible for testing, and decisions about single-step or multiple-step testing. At the end is a treatment decision. New regimens introduce several new variables to consider when deciding which algorithms are most eff ective, and data to inform this decision will be scarce at the time any new regimen is introduced. Mathematical models can be useful to guide decision making in such instances in which direct data are scarce. 52 Such models use existing data to simulate simplifi ed tuberculosis epidemics that behave according to best current knowledge. These models can then be used to project the medium-term incidence and prevalence of drug-resistant tuberculosis at the population level under various assumptions about the deployment of new regimens and corresponding DST.
For example, one priority question is where DST should be placed in treatment algorithms for various epidemiological and economic contexts. Clearly, the ideal algorithm (from a perspective of reducing drug resistance) is to deploy DST for all people with confi rmed or suspected tuberculosis, with confi rmatory testing of preliminary positives. Preliminary modelling has suggested that the so-called test-early strategy for isoniazid and rifampicin might be cost eff ective in areas with an underlying MDR tuberculosis prevalence as low as 2·1%. 53 However, this strategy is only feasible in areas where good DST exists for a given regimen, resources are suffi cient to deploy such DST widely, and use of DST will not greatly delay initiation Series of treatment. Most high-burden settings therefore cannot consider such algorithms at this time.
A history of previous treatment is a strong independent risk factor for resistance, so DST should be directed at these subpopulations. But when should DST be implemented more broadly? For large public health programmes in resource-limited high-burden countries, it might make sense to implement DST only when the prevalence of resistance to a given drug rises above a specifi c threshold. Below this level, the implementation challenges and issue of false positives outweigh the risks from undetected resistance. Above this level, action is needed to prevent worsening treatment outcomes, resistance amplifi cation, and increased transmission. But generally the point at which this threshold should be set in diff erent epidemiological and economic conditions is unclearespecially when MDR tuberculosis hot spots occur within countries that otherwise have low overall prevalence. 54 The answer will also vary depending on whether the remaining drugs in the regimen will still protect the person from resistance generation and disease progression. Modelling could help to assess which thresholds make sense in terms of public health benefi t, cost, and cost-eff ectiveness.
Two questions have arisen in discussions of modelling DST in the context of new tuberculosis regimens. First, what would diff erent DST assays-with diff erent speed, accuracy, price, and technical specifi cations (ie, which drugs, how many mutations)-achieve in terms of a population-level eff ect and cost-eff ectiveness, and what are the trade-off s between these various specifi cations? Second, what is the population-level eff ect and costeff ectiveness of diff erent DST algorithms (eg, DST for all, DST for only patients who are being re-treated or in whom previous treatment had failed, or use of new regimens without DST) as a function of baseline drug resistance and rate of emerging resistance?
Those deciding how to deploy DST should consider the projected epidemiological outcomes, budgetary constraints, feasibility concerns, and political realities. Mathematical models can assist with the fi rst of these (projections of potential outcomes), and thereby serve as an important tool for decision makers. However, these models are restricted by the quality of data; in particular, data are sparse for the extent of drug resistance in many high-burden areas and the rate at which resistance to second-line drugs (eg, fl uoroquinolones) might emerge under pressure from new regimens. Thus, even when restricted to the outcomes issue, mathematical models cannot validate which assumptions about emergence of drug resistance are correct. However, they can project epidemiological outcomes under best-guess assumptions of these datapoints, describe the range of uncertainty, emphasise the data for which surveillance is most crucial as new regimens are deployed, and provide preliminary guidance in line with current knowledge while those data are obtained.
Development of new DST assays
Information about resistance rates (from surveillance) and algorithm choice (from modelling) can directly inform the fi nal question: what new DST assays need to be developed? A target product profi le (TPP) is a list of product specifi cations, including projected product performance and target patient population. The TPP of a DST assay will vary depending on the intended use (individual treatment decisions vs surveillance), the epidemiology (detecting low vs high resistance), the health-system context (where it is positioned in possible algorithms), and whether the technology will be used in central or peripheral settings.
Example TPPs and DST approaches have been described elsewhere. 55, 56 Beyond the target drug(s), these TPPs should address several issues: what is meant by rapid; what level of sensitivity and specifi city a DST assay needs for it to be practical and feasible; what other diseases should be able to use the same DST platform technology; and what level of complexity, containment, and cost are needed.
But two related issues stand out. First, should DST be bundled into case-detection assays (as with the Xpert MTB/RIF assay), or should it be a refl ex test that is done only after tuberculosis is diagnosed? Of the two approaches, refl ex testing needs more patient samples (and potentially more patient visits, with associated loss to follow-up and delays in treatment initiation). But refl ex testing means that only patients with confi rmed, rather than suspected, tuberculosis undergo DST, which can greatly reduce costs.
Second, new DST assays could be developed for deployment at either centralised laboratories or the more (table) . Emerging technologies for DST are abundant-including microarrays, next-generation sequencing, line-probe assays, molecular beacons, high-resolution melt curve analysis, lights on/lights off technology, cyclic catcher melt temperature analysis, phenotypic colour tests, pyrazinamidase assays, and combination phage and molecular assays-and some of these technologies can be readily adapted to increase the number of mutations detected, but few are suited to use in peripheral laboratories. Therefore, investment will be needed either to develop cost-eff ective and robust DST methods for peripheral laboratories, or to create rapid, reliable sample transport systems to support centralised DST (along with mobilehealth and patient-incentive solutions to reduce delays and dropouts). Deployment of testing at the point of treatment can bring obvious advantages, such as reduced delay and dropout, but can add substantially to the overall cost because of the many instruments needed and the lower volumes of testing per site. 57 Many countries diagnose drug-sensitive tuberculosis at the peripheral levels of the health system, but initiate treatment at the subdistrict level. Therefore, a compromise might be to have a new, sensitive casedetection assay as a true point-of-care assay, followed by DST given as a refl ex assay at subdistrict level at the time of treatment initiation.
If non-centralised DST remains the strategy, simplicity should be a major goal. 58 Simplifi ed smear microscopy algorithms provide an interesting example of how upfront performance (in this case, sensitivity) is sometimes worth sacrifi cing in return for a protocol that is simpler for the patient (with lower travel costs) and that therefore is associated with less dropout and better overall eff ectiveness. 59, 60 Modelling studies 61, 62 have already resulted in similar conclusions for new diagnostics. Improved assay sensitivity provides some epidemiological gains, but the greater population eff ect comes from a focus on test specifi cations that allow peripheral use and fast turnaround times, thus reducing patient delays and default. 61, 62 One option for a peripheral laboratory test is to focus on excluding all patients who are likely to be resistant; high sensitivity becomes the goal and specifi city becomes less important. A test with lower specifi city can be acceptable if the prevalence of resistance is high, if an eff ective and safe alternative regimen (eg, 2HRZE/4RH for PaMZ) is available, or if used as a triage test. One example of an approach that prioritises sensitivity is the proposed molecular assay to screen for the wild-type pncA gene as a correlate for pyrazinamide susceptibility, rather than trying to capture the many diff erent pncA mutations that can lead to pyrazinamide resistance. Another option is to continue-even with new regimens-to focus on rifampicin resistance screening as a fi rst step. Preliminary evidence 17 suggests that rifampicin-resistant strains are more likely than rifampicin-sensitive strains to be resistant to pyrazinamide and fl uoroquinolones. Therefore, DST for rifampicin might be a useful triage test even if the fi rstline regimen does not contain rifampicin (eg, PaMZ). The subsequent pyrazinamide and fl uoroquinolone DST could then be restricted to a smaller population with a higher prevalence of resistance.
All of this theory is irrelevant unless companies invest in the development and testing of new tuberculosis diagnostics. These developers should be aware of what is needed in resource-limited settings and be willing to take a product all the way through fi eld testing to Panel 2: Framework to achieve successful implementation of new tuberculosis regimens and drug susceptibility testing (DST)
Short term
• Identify all mutations in Mycobacterium tuberculosis that occur reasonably frequently and that result in resistance to existing and new drugs; priority should be placed on obtaining resistance information from clinical samples that are accompanied by treatment outcome data • Develop a collection of sequenced sensitive and resistant strains that can be used to assess new DST assays • Use modelling to defi ne which strategies for deployment of DST will have the greatest population-level eff ect and be most cost eff ective; various strategies would include diff erent DST assays that vary in their speed, sensitivity and specifi city, cost, and technical specifi cations and diff erent DST algorithms, used in the context of various baseline resistance levels • Undertake surveillance of moxifl oxacin resistance in new patients with tuberculosis and of pyrazinamide resistance in new and previously treated patients, and patients with and without multidrug-resistant tuberculosis • Do operational research to assess and optimise systems for sputum transport and reporting results (including prompt initiation of treatment in response) • Develop clear target product profi les to guide diagnostics developers about the necessary product specifi cations and likely market demand • Do analyses of the tuberculosis diagnostics market size and potential to inform investment decisions by test developers
Medium term
• Use existing diagnostics platforms to develop, fi eld test, and commercialise DST assays-particularly for fl uoroquinolones and pyrazinamide-that can be implemented at the subdistrict level • Monitor for clinical resistance generated during the roll-out of new tuberculosis drugs (ie, new chemical entities) and identify the molecular basis for such resistance • Refi ne models of long-term impact based on early surveillance data during roll-out of novel regimens • Develop DST assays for new tuberculosis drugs and use them to do ongoing surveillance • Develop and strengthen systems for using next-generation sequencing for tuberculosis drug surveillance
Long term
• Develop new diagnostic platforms that are rapid, inexpensive, and can be implemented at the subdistrict level • Develop a universal regimen for tuberculosis that has at least three novel chemical entities and that therefore minimises the need for DST while treating all forms of tuberculosis Series commercialisation. The perception that these assays have little commercial opportunity is a substantial barrier to development, and supportive fi nancing will probably still be needed. In addition to the TPP issues listed previously, diagnostics developers are interested in potential market size and the practical steps needed for test development, validation, regulation, and policy (panel 1). 63 Developers targeting surveillance have a particularly small market, although the barrier to entry is much lower because these high-throughput, centralised machines can be built on the presumption that users will have a high level of skill and that the machine will have applications beyond tuberculosis. For developers interested in peripheral DST for patient care, the demands in terms of assay simplifi cation and robustness increase greatly, and market size is very dependent on the resistance thresholds for testing. Test developers might therefore be more interested in a product that combines tuberculosis detection and DST because this product will have a larger market than a DST-only product.
Private sector procurement is a major strategic gap. If new DST assays are highly priced, few private practitioners will use them, and DST will be missing from the sector that is most likely to adopt new drugs quickly and in the context of variable regimens. To solve this issue, a mechanism is needed to ensure that private laboratories pass along any savings from assays purchased at concessionary prices.
Although demonstration projects for diagnostics need substantial investment, assay development with existing platforms can be cheap by comparison. But even to make these investments, diagnostic companies need a prediction of user needs (where the user is often a national tuberculosis programme) and market demand. Defi ning a clear set of specifi cations for the desired DST-and the likely demand for such DST-is the next major point of collaboration for drug and diagnostic developers.
Conclusion
The prospect of new tuberculosis regimens is exciting, because patients have had to rely on a single lengthy treatment option for decades. Several opportunities are available to mitigate the risks of developing resistance to these new regimens. Assays to detect resistance can be developed before repurposed drugs come to market and early in the implementation of new drugs. Surveillance DST can identify areas where some regimens might be compromised by high levels of background resistance, and treatment decisions can, in some settings, be tailored to the individual by rapid DST before treatment. Modelling studies will help to assess costs, outcomes, and feasibility to predict implementation approaches. Panel 2 outlines a framework to achieve these goals. W hen all of these strategies are brought to bear, drugs and diagnostics will together make a powerful combination.
